Login Register Cart 0
Generic placeholder image

Current Women`s Health Reviews

Editor-in-Chief

ISSN (Print): 1573-4048
ISSN (Online): 1875-6581

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

An Exquisite Analysis on the Significance of Nutrient Supplementation in the Holistic Management of Poly-cystic Ovarian Syndrome

Author(s): Rashmi Saxena Pal*, Yogendra Pal, Motamarri Venkata Naga Lalitha Chaitanya, Rajnish Kumar, Pankaj Tyagi and Preeti Srivastava

Volume 20, Issue 6, 2024

Published on: 11 October, 2023

Article ID: e111023222108 Pages: 10

DOI: 10.2174/0115734048262284230927191823

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

The complex heterogeneous disorder known as polycystic ovarian syndrome (PCOS) includes endocrine, reproductive, metabolic, psychological, and other pathological aspects. Yet, nothing is understood regarding the cause of PCOS. Insulin resistance and hyperandrogenism are major contributors to the pathophysiology of PCOS, according to various studies. Because of this, a lot of PCOS treatment regimens include changing a person's lifestyle through practices, like exercise, nutrition, and vitamin supplementation. Recent studies have indicated a number of nutrients, including vitamins, minerals, and vitamin-like substances, for the therapy of PCOS since they all have at least one functional characteristic in the pathways that are affected by PCOS. As a result, it is claimed that PCOS may be caused by a vitamin or mineral deficiency. It is the goal of this review to conduct a critical literature analysis on nutritional supplementation for the management of PCOS.

Keywords: Polycystic ovary syndrome, insulin resistance, metabolic disorders, dietary supplements, vitamin, menstral disruption.

[1]
Pundir, C.S.; Deswal, R.; Narwal, V.; Dang, A. The prevalence of polycystic ovary syndrome: A brief systematic review. J. Hum. Reprod. Sci., 2020, 13(4), 261-271.
[http://dx.doi.org/10.4103/jhrs.JHRS_95_18] [PMID: 33627974]
[2]
Bani, M.M.; Majdi, S.A. Polycystic ovary syndrome (PCOS), Diagnostic criteria, and AMH. Asian Pac J Cancer Prev, 2017, 18(1), 17-21.
[PMID: 28240001]
[3]
Rosenfield, R.L.; Ehrmann, D.A. The pathogenesis of polycystic ovary syndrome (PCOS): The hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr. Rev., 2016, 37(5), 467-520.
[http://dx.doi.org/10.1210/er.2015-1104] [PMID: 27459230]
[4]
Ndefo, U.A.; Eaton, A.; Green, M.R. Polycystic ovary syndrome: A review of treatment options with a focus on pharmacological approaches. P&T, 2013, 38(6), 336-355.
[PMID: 23946629]
[5]
Gullo, G.; Scaglione, M.; Cucinella, G.; Perino, A.; Chiantera, V.; D’Anna, R.; Laganà, A.S.; Buzzaccarini, G. Impact of assisted reproduction techniques on the neuro-psycho-motor outcome of newborns: A critical appraisal. J. Obstet. Gynaecol., 2022, 42(7), 2583-2587.
[http://dx.doi.org/10.1080/01443615.2022.2109953] [PMID: 35959847]
[6]
Günalan, E.; Yaba, A.; Yılmaz, B. The effect of nutrient supplementation in the management of polycystic ovary syndrome-associated metabolic dysfunctions: A critical review. J. Turk. Ger. Gynecol. Assoc., 2018, 19(4), 220-232.
[http://dx.doi.org/10.4274/jtgga.2018.0077] [PMID: 30299265]
[7]
Witchel, S.F.; Oberfield, S.E.; Peña, A.S. Polycystic ovary syndrome: Pathophysiology, presentation, and treatment with emphasis on adolescent girls. J. Endocr. Soc., 2019, 3(8), 1545-1573.
[http://dx.doi.org/10.1210/js.2019-00078] [PMID: 31384717]
[8]
Ding, H.; Zhang, J.; Zhang, F.; Zhang, S.; Chen, X.; Liang, W.; Xie, Q. Resistance to the insulin and elevated level of androgen: A major cause of polycystic ovary syndrome. Front. Endocrinol., 2021, 12, 741764.
[http://dx.doi.org/10.3389/fendo.2021.741764] [PMID: 34745009]
[9]
Sheehan, M.T. Polycystic ovarian syndrome: Diagnosis and management. Clin. Med. Res., 2004, 2(1), 13-27.
[http://dx.doi.org/10.3121/cmr.2.1.13] [PMID: 15931331]
[10]
Calcaterra, V.; Verduci, E.; Cena, H.; Magenes, V.C.; Todisco, C.F.; Tenuta, E.; Gregorio, C.; De Giuseppe, R.; Bosetti, A.; Di Profio, E.; Zuccotti, G. Polycystic ovary syndrome in insulin-resistant adolescents with obesity: The role of nutrition therapy and food supplements as a strategy to protect fertility. Nutrients, 2021, 13(6), 1848.
[http://dx.doi.org/10.3390/nu13061848] [PMID: 34071499]
[11]
Kondapaneni, V.; Gutlapalli, S.D.; Poudel, S.; Zeb, M.; Toulassi, I.A.; Cancarevic, I. Significance of homocysteine levels in the management of polycystic ovarian syndrome: A literature review. Cureus, 2020, 12(10), e11110.
[http://dx.doi.org/10.7759/cureus.11110] [PMID: 33240706]
[12]
Kaye, A.D.; Jeha, G.M.; Pham, A.D.; Fuller, M.C.; Lerner, Z.I.; Sibley, G.T.; Cornett, E.M.; Urits, I.; Viswanath, O.; Kevil, C.G. Folic acid supplementation in patients with elevated homocysteine levels. Adv. Ther., 2020, 37(10), 4149-4164.
[http://dx.doi.org/10.1007/s12325-020-01474-z] [PMID: 32845472]
[13]
National Institutes of Health. Thiamin. Available from: https://ods.od.nih.gov/factsheets/Thiamin-HealthProfessional/ (Accessed on: 12 April,2023).
[14]
Martinez, D.L.; Tsuchiya, Y.; Gout, I. Coenzyme A biosynthetic machinery in mammalian cells. Biochem. Soc. Trans., 2014, 42(4), 1112-1117.
[http://dx.doi.org/10.1042/BST20140124] [PMID: 25110011]
[15]
Spinneker, A.; Sola, R.; Lemmen, V.; Castillo, M.J.; Pietrzik, K.; González-Gross, M. Vitamin B6 status, deficiency and its consequences--an overview. Nutr. Hosp., 2007, 22(1), 7-24.
[PMID: 17260529]
[16]
National Institutes of Health. Niacin. Available from: https://ods.od.nih.gov/factsheets/Niacin-HealthProfessional/ (Accessed on: 12 April,2023).
[17]
Berdanier, C.D.; Berdanier, L. Advanced Nutrition: Macronutrients, Micronutrients, and Metabolism, 2nd ed.; CRC Press: Oakville, 2015.
[18]
Czumaj, A; Szrok-Jurga, S; Hebanowska, A The pathophysiological role of CoA. Int J Mol Sci., 2020, 21(23), 9057.
[http://dx.doi.org/10.3390/ijms21239057]
[19]
Miller, J.W.; Rucker, R.B. Pantothenic Acid. Present Knowledge in Nutrition, 10th ed; Wiley-Blackwell: Hoboken, NJ, USA, 2012, pp. 375-390.
[http://dx.doi.org/10.1002/9781119946045.ch24]
[20]
National Institutes of Health. Vitamin B6., Available from: https://ods.od.nih.gov/factsheets/Vitamin B6-HealthProfessional/ (Accessed on: 12 April,2023).
[21]
Spinneker, A.; Sola, R.; Lemmen, V.; Castillo, M. J.; Pietrzik, K.; González-Gross, M. Vitamin B6 status, deficiency and its consequences - an overview Hospital Nutrition. Nutr Hosp., 2007, 22(1), 7-24.
[22]
Milman, N. Intestinal absorption of folic acid - new physiologic & molecular aspects. Indian J. Med. Res., 2012, 136(5), 725-728.
[PMID: 23287118]
[23]
de Benoist, B. Conclusions of a WHO technical consultation on folate and vitamin B12 deficiencies. Food Nutr. Bull., 2008, 29(S2), S238-S244.
[http://dx.doi.org/10.1177/15648265080292S129] [PMID: 18709899]
[24]
Rojas, J.; Chávez, M.; Olivar, L.; Rojas, M.; Morillo, J.; Mejías, J.; Calvo, M.; Bermúdez, V. Polycystic ovary syndrome, insulin resistance, and obesity: Navigating the pathophysiologic labyrinth. Int. J. Reprod. Med., 2014, 2014, 1-17.
[http://dx.doi.org/10.1155/2014/719050] [PMID: 25763405]
[25]
Dominguez, L.J.; Farruggia, M.; Veronese, N.; Barbagallo, M.; Vitamin, D. Vitamin D sources, metabolism, and deficiency: Available compounds and guidelines for its treatment. Metabolites, 2021, 11(4), 255.
[http://dx.doi.org/10.3390/metabo11040255] [PMID: 33924215]
[26]
Menichini, D.; Forte, G.; Orrù, B.; Gullo, G.; Unfer, V.; Facchinetti, F. The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review. Int. J. Vitam. Nutr. Res., 2022, 92(2), 126-133.
[http://dx.doi.org/10.1024/0300-9831/a000691] [PMID: 33284035]
[27]
Niki, E. Role of vitamin E as a lipid-soluble peroxyl radical scavenger: In vitro and in vivo evidence. Free Radic. Biol. Med., 2014, 66, 3-12.
[http://dx.doi.org/10.1016/j.freeradbiomed.2013.03.022] [PMID: 23557727]
[28]
Liao, S.; Omage, S.O.; Börmel, L.; Kluge, S.; Schubert, M.; Wallert, M.; Lorkowski, S. Vitamin E and metabolic health: Relevance of interactions with other micronutrients. Antioxidants, 2022, 11(9), 1785.
[http://dx.doi.org/10.3390/antiox11091785] [PMID: 36139859]
[29]
Tripathi, A.K.; Ray, A.K.; Mishra, S.K.; Bishen, S.M.; Mishra, H.; Khurana, A. Molecular and therapeutic insights of alpha-lipoic acid as a potential molecule for disease prevention. Rev. Bras. Farmacogn., 2023, 33(2), 272-287.
[http://dx.doi.org/10.1007/s43450-023-00370-1] [PMID: 36778891]
[30]
Toosy, S.; Sodi, R.; Pappachan, J.M. Lean polycystic ovary syndrome (PCOS): An evidence-based practical approach. J. Diabetes Metab. Disord., 2018, 17(2), 277-285.
[http://dx.doi.org/10.1007/s40200-018-0371-5] [PMID: 30918863]
[31]
Chen, W.; Pang, Y. Metabolic syndrome and PCOS: Pathogenesis and the role of metabolites. Metabolites, 2021, 11(12), 869.
[http://dx.doi.org/10.3390/metabo11120869] [PMID: 34940628]
[32]
De Leo, V.; Musacchio, M.C.; Cappelli, V.; Massaro, M.G.; Morgante, G.; Petraglia, F. Genetic, hormonal and metabolic aspects of PCOS: An update. Reprod. Biol. Endocrinol., 2016, 14(1), 38.
[http://dx.doi.org/10.1186/s12958-016-0173-x] [PMID: 27423183]
[33]
Fenkci, S.M.; Fenkci, V.; Oztekin, O.; Rota, S.; Karagenc, N. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Hum. Reprod., 2008, 23(7), 1602-1606.
[http://dx.doi.org/10.1093/humrep/den109] [PMID: 18378560]
[34]
Zhao, X.; Feng, X.; Zhao, X.; Jiang, Y.; Li, X.; Niu, J.; Meng, X.; Wu, J.; Xu, G.; Hou, L.; Wang, Y. How to screen and prevent metabolic syndrome in patients of PCOS early: Implications from metabolomics. Front. Endocrinol., 2021, 12, 659268.
[http://dx.doi.org/10.3389/fendo.2021.659268] [PMID: 34149613]
[35]
Rodríguez-Varela, C.; Labarta, E. Clinical application of antioxidants to improve human oocyte mitochondrial function: A review. Antioxidants, 2020, 9(12), 1197.
[http://dx.doi.org/10.3390/antiox9121197] [PMID: 33260761]
[36]
Rodríguez-Varela, C.; Labarta, E. Does coenzyme Q10 supplementation improve human oocyte quality? Int. J. Mol. Sci., 2021, 22(17), 9541.
[http://dx.doi.org/10.3390/ijms22179541] [PMID: 34502447]
[37]
ElObeid, T.; Awad, M.O.; Ganji, V.; Moawad, J. The impact of mineral supplementation on polycystic ovarian syndrome. Metabolites, 2022, 12(4), 338.
[http://dx.doi.org/10.3390/metabo12040338] [PMID: 35448525]
[38]
Sam, S. Obesity and polycystic ovary syndrome. Obes. Manag., 2007, 3(2), 69-73.
[http://dx.doi.org/10.1089/obe.2007.0019] [PMID: 20436797]
[39]
Costello, R.B.; Dwyer, J.T.; Bailey, R.L. Chromium supplements for glycemic control in type 2 diabetes: Limited evidence of effectiveness. Nutr. Rev., 2016, 74(7), 455-468.
[http://dx.doi.org/10.1093/nutrit/nuw011] [PMID: 27261273]
[40]
Amiri Siavashani, M.; Zadeh Modarres, S.; Mirhosseini, N.; Aghadavod, E.; Salehpour, S.; Asemi, Z. The effects of chromium supplementation on gene expression of insulin, lipid, and inflammatory markers in infertile women with polycystic ovary syndrome candidate for in vitro Fertilization: A randomized, double-blinded, placebo-controlled trial. Front. Endocrinol., 2018, 9, 726.
[http://dx.doi.org/10.3389/fendo.2018.00726] [PMID: 30546347]
[41]
Ashcroft, F.M. ATP-sensitive potassium channelopathies: Focus on insulin secretion. J. Clin. Invest., 2005, 115(8), 2047-2058.
[http://dx.doi.org/10.1172/JCI25495] [PMID: 16075046]
[42]
Fridlyand, L.E.; Jacobson, D.A.; Philipson, L.H. Ion channels and regulation of insulin secretion in human β-cells. Islets, 2013, 5(1), 1-15.
[http://dx.doi.org/10.4161/isl.24166] [PMID: 23624892]
[43]
Alesi, S.; Ee, C.; Moran, L.J.; Rao, V.; Mousa, A. Nutritional supplements and complementary therapies in polycystic ovary syndrome. Adv. Nutr., 2022, 13(4), 1243-1266.
[http://dx.doi.org/10.1093/advances/nmab141] [PMID: 34970669]
[44]
Rayman, M.P.; Thompson, A.J.; Bekaert, B.; Catterick, J.; Galassini, R.; Hall, E.; Warren-Perry, M.; Beckett, G.J. Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom. Am. J. Clin. Nutr., 2008, 87(2), 370-378.
[http://dx.doi.org/10.1093/ajcn/87.2.370] [PMID: 18258627]
[45]
Chausmer, A.B. Zinc, insulin and diabetes. J. Am. Coll. Nutr., 1998, 17(2), 109-115.
[http://dx.doi.org/10.1080/07315724.1998.10718735] [PMID: 9550453]
[46]
Grădinaru, D.; Margină, D.; Ungurianu, A.; Nițulescu, G.; Pena, C.; Ionescu-Tîrgoviște, C.; Miulescu, R. Zinc status, insulin resistance and glycoxidative stress in elderly subjects with type 2 diabetes mellitus. Exp. Ther. Med., 2021, 22(6), 1393.
[http://dx.doi.org/10.3892/etm.2021.10829] [PMID: 34650641]
[47]
Guo, Y.M.; Sun, T.C.; Wang, H.P.; Chen, X. Research progress of melatonin (MT) in improving ovarian function: A review of the current status. Aging., 2021, 13(13), 17930-17947.
[http://dx.doi.org/10.18632/aging.203231] [PMID: 34228638]
[48]
Mojaverrostami, S.; Asghari, N.; Khamisabadi, M.; Heidari Khoei, H. The role of melatonin in polycystic ovary syndrome: A review. Int. J. Reprod. Biomed., 2019, 17(12), 865-882.
[http://dx.doi.org/10.18502/ijrm.v17i12.5789] [PMID: 31970309]
[49]
Sun, W.S.; Jang, H.; Park, M.R.; Oh, K.B.; Lee, H.; Hwang, S.; Xu, L.J.; Hwang, I.S.; Lee, J.W. N-acetyl-L-cysteine improves the developmental competence of bovine oocytes and embryos cultured in vitro by attenuating oxidative damage and apoptosis. Antioxidants, 2021, 10(6), 860.
[http://dx.doi.org/10.3390/antiox10060860] [PMID: 34071998]
[50]
Norman, R.J.; Dewailly, D.; Legro, R.S.; Hickey, T.E. Polycystic ovary syndrome. Lancet, 2007, 370(9588), 685-697.
[http://dx.doi.org/10.1016/S0140-6736(07)61345-2] [PMID: 17720020]
[51]
Epstein, F.H.; Moller, D.E.; Flier, J.S. Insulin resistance--mechanisms, syndromes, and implications. N. Engl. J. Med., 1991, 325(13), 938-948.
[http://dx.doi.org/10.1056/NEJM199109263251307] [PMID: 1881419]
[52]
Oner, G.; Muderris, I.I. Clinical, endocrine and metabolic effects of metformin vs N-acetyl-cysteine in women with polycystic ovary syndrome. Eur. J. Obstet. Gynecol. Reprod. Biol., 2011, 159(1), 127-131.
[http://dx.doi.org/10.1016/j.ejogrb.2011.07.005] [PMID: 21831508]
[53]
Javanmanesh, F.; Kashanian, M.; Rahimi, M.; Sheikhansari, N. A comparison between the effects of metformin and N -acetyl cysteine (NAC) on some metabolic and endocrine characteristics of women with polycystic ovary syndrome. Gynecol. Endocrinol., 2016, 32(4), 285-289.
[http://dx.doi.org/10.3109/09513590.2015.1115974] [PMID: 26654154]
[54]
Yang, K.; Zeng, L.; Bao, T.; Ge, J. Effectiveness of Omega-3 fatty acid for polycystic ovary syndrome: A systematic review and meta-analysis. Reprod Biol Endocrinol., 2018, 16(1), 27.
[55]
Cowan, S.; Lim, S.; Alycia, C.; Pirotta, S.; Thomson, R.; Gibson-Helm, M.; Blackmore, R.; Naderpoor, N.; Bennett, C.; Ee, C.; Rao, V.; Mousa, A.; Alesi, S.; Moran, L. Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity. BMC Endocr. Disord., 2023, 23(1), 14.
[http://dx.doi.org/10.1186/s12902-022-01208-y] [PMID: 36647089]
[56]
Sherratt, S.C.R.; Libby, P.; Budoff, M.J.; Bhatt, D.L.; Mason, R.P. Role of omega-3 fatty acids in cardiovascular disease: The debate continues. Curr. Atheroscler. Rep., 2023, 25(1), 1-17.
[http://dx.doi.org/10.1007/s11883-022-01075-x] [PMID: 36580204]
[57]
Alagawany, M.; Elnesr, S.S.; Farag, M.R.; Abd El-Hack, M.E.; Khafaga, A.F.; Taha, A.E.; Tiwari, R.; Yatoo, M.I.; Bhatt, P.; Khurana, S.K.; Dhama, K. Omega-3 and omega-6 fatty acids in poultry nutrition: Effect on production performance and health. Animals., 2019, 9(8), 573.
[http://dx.doi.org/10.3390/ani9080573] [PMID: 31426600]
[58]
Koushki, M.; Amiri-Dashatan, N.; Ahmadi, N.; Abbaszadeh, H.A.; Rezaei-Tavirani, M. Resveratrol: A miraculous natural compound for diseases treatment. Food Sci. Nutr., 2018, 6(8), 2473-2490.
[http://dx.doi.org/10.1002/fsn3.855] [PMID: 30510749]
[59]
Ghowsi, M.; Khazali, H.; Sisakhtnezhad, S. The effect of resveratrol on oxidative stress in the liver and serum of a rat model of polycystic ovary syndrome: An experimental study. Int. J. Reprod. Biomed., 2018, 16(3), 149-158.
[http://dx.doi.org/10.29252/ijrm.16.3.149] [PMID: 29766146]
[60]
Wilcox, G. Insulin and insulin resistance. Clin. Biochem. Rev., 2005, 26(2), 19-39.
[PMID: 16278749]
[61]
Kalra, S.; Kalra, B.; Sharma, J.B. The inositols and polycystic ovary syndrome. Indian J. Endocrinol. Metab., 2016, 20(5), 720-724.
[http://dx.doi.org/10.4103/2230-8210.189231] [PMID: 27730087]
[62]
Wojciechowska, A.; Osowski, A.; Jóźwik, M.; Górecki, R.; Rynkiewicz, A.; Wojtkiewicz, J. Inositols’ importance in the improvement of the endocrine–metabolic profile in PCOS. Int. J. Mol. Sci., 2019, 20(22), 5787.
[http://dx.doi.org/10.3390/ijms20225787] [PMID: 31752081]
[63]
Hemarajata, P.; Versalovic, J. Effects of probiotics on gut microbiota: Mechanisms of intestinal immunomodulation and neuromodulation. Therap. Adv. Gastroenterol., 2013, 6(1), 39-51.
[http://dx.doi.org/10.1177/1756283X12459294] [PMID: 23320049]
[64]
Wang, X.; Zhang, P.; Zhang, X. Probiotics regulate gut microbiota: An effective method to improve immunity. Molecules, 2021, 26(19), 6076.
[http://dx.doi.org/10.3390/molecules26196076] [PMID: 34641619]
[65]
Duan, L.; An, X.; Zhang, Y.; Jin, D.; Zhao, S.; Zhou, R.; Duan, Y.; Zhang, Y.; Liu, X.; Lian, F. Gut microbiota as the critical correlation of polycystic ovary syndrome and type 2 diabetes mellitus. Biomed. Pharmacother., 2021, 142, 112094.
[http://dx.doi.org/10.1016/j.biopha.2021.112094] [PMID: 34449321]
[66]
Singh, S.; Pal, N.; Shubham, S.; Sarma, D.K.; Verma, V.; Marotta, F.; Kumar, M. Polycystic ovary syndrome: Etiology, current management, and future therapeutics. J. Clin. Med., 2023, 12(4), 1454.
[http://dx.doi.org/10.3390/jcm12041454] [PMID: 36835989]
[67]
Gu, Y.; Zhou, G.; Zhou, F.; Li, Y.; Wu, Q.; He, H.; Zhang, Y.; Ma, C.; Ding, J.; Hua, K. Gut and vaginal microbiomes in PCOS: Implications for women’s health. Front. Endocrinol., 2022, 13, 808508.
[http://dx.doi.org/10.3389/fendo.2022.808508] [PMID: 35282446]

Rights & Permissions Print Cite
Article Metrics
7
2
Wayfinder Image
Open Access Journals Promotions
© 2024 Bentham Science Publishers | Privacy Policy